<p>ProKidney Corp.（纳斯达克代码：PROK - 获取免费报告）周四下跌了 5.5%。该公司的股价最低跌至$2.15，最后交易价为$2.1550。在午盘交易中，共交易了 358,174 股，较平均交易量 973,694 股下降了 63%。该股票此前收盘价为$2.28。</p>
<h2>华尔街分析师预测增长</h2>
<p>一些股票分析师最近对 PROK 股票发表了评论。Weiss Ratings 在 10 月 8 日星期三的报告中重申了对 ProKidney 的 “卖出（d-）” 评级。HC Wainwright 在 12 月 16 日星期二的研究报告中开始覆盖 ProKidney 股票。他们对该股票设定了 “买入” 评级和$12.00 的目标价。四位分析师给予该股票 “买入” 评级，一位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “持有”，平均目标价为$7.40。</p>
<p><strong>查看我们最新的 PROK 股票报告</strong></p>
<h2>ProKidney 股票表现</h2>
<p>该公司的 50 日移动平均价格为$2.34，200 日移动平均价格为$2.59。该公司的市值为 6.6032 亿美元，市盈率为-3.99，贝塔值为 1.79。</p>
<p>ProKidney（纳斯达克代码：PROK - 获取免费报告）最近于 11 月 10 日星期一发布了季度财报。该公司报告季度每股收益为（$0.12），符合分析师的共识预期（$0.12）。该业务在季度内的收入为 22 万美元，而分析师预期为 4 万美元。整体来看，分析师预计 ProKidney Corp.在本年度将发布每股收益为-0.57。</p>
<h2>ProKidney 内部活动</h2>
<p>在相关消息中，董事 Brian Jg Pereira 于 11 月 13 日星期四出售了 502,136 股该公司的股票。股票以平均价格$2.37 出售，总价值为$1,190,062.32。此次出售已在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。41.49% 的股票由公司内部人士持有。</p>
<h2>机构投资者对 ProKidney 的看法</h2>
<p>机构投资者和对冲基金最近增加或减少了对该公司的持股。Zullo Investment Group Inc.在第三季度购买了 ProKidney 的新股份，价值$28,000。Catalyst Funds Management Pty Ltd 在第二季度收购了 ProKidney 的新股份，价值约$36,000。AQR Capital Management LLC 在第一季度将其在 ProKidney 的持股增加了 106.4%。AQR Capital Management LLC 现在拥有 52,570 股该公司的股票，价值$46,000，此前在上个季度又购买了 27,098 股。Jefferies Financial Group Inc.在第三季度收购了 ProKidney 的新股份，价值约$158,000。最后，Virtu Financial LLC 在第三季度收购了 ProKidney 的新股份，价值约$203,000。对冲基金和其他机构投资者持有该公司 51.59% 的股票。</p>
<h2>关于 ProKidney</h2>
<p>（获取免费报告）</p>
<p>ProKidney, Inc.（纳斯达克代码：PROK）是一家临床阶段的生物技术公司，专注于开发针对肾脏疾病的细胞治疗。该公司的研究和开发活动集中在利用人源近端小管细胞来解决急性肾损伤（AKI）和慢性肾病（CKD）等疾病。通过针对肾脏损伤和功能障碍的基础细胞机制，ProKidney 旨在提供超越当前支持性护理选项的新型再生医学方法。</p>
<p>ProKidney 的主要项目利用专有方法分离和扩展肾上皮细胞，以创建可注射的治疗产品。</p>
<h2>另请参阅</h2>
<ul>
<li>五只我们更看好的股票，胜过 ProKidney</li>
<li>Elon 将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>执行命令 14330：特朗普最大的一次</li>
<li>崩盘已经开始（大多数人只是还没看到）</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 ProKidney 吗？</h2>
<p>在考虑 ProKidney 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 ProKidney 并不在名单上。</p>
<p>虽然 ProKidney 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PROK

<p>ProKidney Corp.（纳斯达克代码：PROK）股价下跌 5.5%，至 2.1550 美元，交易量较平均水平下降 63%。分析师的评级意见不一，Weiss Ratings 给出 “卖出” 评级，而 HC Wainwright 则给予 “买入” 评级，目标价为 12 美元。该股票的共识评级为 “持有”，平均目标价为 7.40 美元。ProKidney 报告的季度每股收益为（0.12 美元），收入为 22 万美元。机构投资者持有 51.59% 的股份，公司专注于肾脏疾病的细胞治疗</p>

<p>ProKidney Corp. (NASDAQ:PROK - Get Free Report) fell 5.5% on Thursday . The company traded as low as $2.15 and last traded at $2.1550. 358,174 shares were traded during mid-day trading, a decline of 63% from the average session volume of 973,694 shares. The stock had previously closed at $2.28.</p>
<div class="lb-trans"><p>ProKidney Corp.（纳斯达克代码：PROK - 获取免费报告）周四下跌了 5.5%。该公司的股价最低跌至$2.15，最后交易价为$2.1550。在午盘交易中，共交易了 358,174 股，较平均交易量 973,694 股下降了 63%。该股票此前收盘价为$2.28。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of equities analysts recently commented on PROK shares. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of ProKidney in a report on Wednesday, October 8th. HC Wainwright started coverage on shares of ProKidney in a research report on Tuesday, December 16th. They set a &#34;buy&#34; rating and a $12.00 price target on the stock. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of &#34;Hold&#34; and an average price target of $7.40.</p>
<div class="lb-trans"><p>一些股票分析师最近对 PROK 股票发表了评论。Weiss Ratings 在 10 月 8 日星期三的报告中重申了对 ProKidney 的 “卖出（d-）” 评级。HC Wainwright 在 12 月 16 日星期二的研究报告中开始覆盖 ProKidney 股票。他们对该股票设定了 “买入” 评级和$12.00 的目标价。四位分析师给予该股票 “买入” 评级，一位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “持有”，平均目标价为$7.40。</p>
</div><p><strong>View Our Latest Stock Report on PROK</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 PROK 股票报告</strong></p>
</div><h2>ProKidney Stock Performance</h2>
<div class="lb-trans"><h2>ProKidney 股票表现</h2>
</div><p>The company's 50-day moving average price is $2.34 and its 200-day moving average price is $2.59. The firm has a market capitalization of $660.32 million, a PE ratio of -3.99 and a beta of 1.79.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均价格为$2.34，200 日移动平均价格为$2.59。该公司的市值为 6.6032 亿美元，市盈率为-3.99，贝塔值为 1.79。</p>
</div><p>ProKidney (NASDAQ:PROK - Get Free Report) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.12) EPS for the quarter, meeting analysts' consensus estimates of ($0.12). The business had revenue of $0.22 million during the quarter, compared to analysts' expectations of $0.04 million. As a group, analysts anticipate that ProKidney Corp. will post -0.57 earnings per share for the current year.</p>
<div class="lb-trans"><p>ProKidney（纳斯达克代码：PROK - 获取免费报告）最近于 11 月 10 日星期一发布了季度财报。该公司报告季度每股收益为（$0.12），符合分析师的共识预期（$0.12）。该业务在季度内的收入为 22 万美元，而分析师预期为 4 万美元。整体来看，分析师预计 ProKidney Corp.在本年度将发布每股收益为-0.57。</p>
</div><h2>Insider Activity at ProKidney</h2>
<div class="lb-trans"><h2>ProKidney 内部活动</h2>
</div><p>In related news, Director Brian Jg Pereira sold 502,136 shares of the business's stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $2.37, for a total value of $1,190,062.32. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. 41.49% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事 Brian Jg Pereira 于 11 月 13 日星期四出售了 502,136 股该公司的股票。股票以平均价格$2.37 出售，总价值为$1,190,062.32。此次出售已在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。41.49% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On ProKidney</h2>
<div class="lb-trans"><h2>机构投资者对 ProKidney 的看法</h2>
</div><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Zullo Investment Group Inc. purchased a new stake in ProKidney in the 3rd quarter valued at $28,000. Catalyst Funds Management Pty Ltd acquired a new stake in shares of ProKidney during the second quarter worth about $36,000. AQR Capital Management LLC grew its holdings in shares of ProKidney by 106.4% during the first quarter. AQR Capital Management LLC now owns 52,570 shares of the company's stock worth $46,000 after buying an additional 27,098 shares during the last quarter. Jefferies Financial Group Inc. acquired a new position in ProKidney in the 3rd quarter valued at about $158,000. Finally, Virtu Financial LLC acquired a new stake in ProKidney during the 3rd quarter worth approximately $203,000. Hedge funds and other institutional investors own 51.59% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近增加或减少了对该公司的持股。Zullo Investment Group Inc.在第三季度购买了 ProKidney 的新股份，价值$28,000。Catalyst Funds Management Pty Ltd 在第二季度收购了 ProKidney 的新股份，价值约$36,000。AQR Capital Management LLC 在第一季度将其在 ProKidney 的持股增加了 106.4%。AQR Capital Management LLC 现在拥有 52,570 股该公司的股票，价值$46,000，此前在上个季度又购买了 27,098 股。Jefferies Financial Group Inc.在第三季度收购了 ProKidney 的新股份，价值约$158,000。最后，Virtu Financial LLC 在第三季度收购了 ProKidney 的新股份，价值约$203,000。对冲基金和其他机构投资者持有该公司 51.59% 的股票。</p>
</div><h2>About ProKidney</h2>
<div class="lb-trans"><h2>关于 ProKidney</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>ProKidney, Inc NASDAQ: PROK is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.</p>
<div class="lb-trans"><p>ProKidney, Inc.（纳斯达克代码：PROK）是一家临床阶段的生物技术公司，专注于开发针对肾脏疾病的细胞治疗。该公司的研究和开发活动集中在利用人源近端小管细胞来解决急性肾损伤（AKI）和慢性肾病（CKD）等疾病。通过针对肾脏损伤和功能障碍的基础细胞机制，ProKidney 旨在提供超越当前支持性护理选项的新型再生医学方法。</p>
</div><p>ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.</p>
<div class="lb-trans"><p>ProKidney 的主要项目利用专有方法分离和扩展肾上皮细胞，以创建可注射的治疗产品。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than ProKidney</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Executive Order 14330: Trump’s Biggest Yet</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 ProKidney</li>
<li>Elon 将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>执行命令 14330：特朗普最大的一次</li>
<li>崩盘已经开始（大多数人只是还没看到）</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in ProKidney Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 ProKidney 吗？</h2>
</div><p>Before you consider ProKidney, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 ProKidney 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProKidney wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 ProKidney 并不在名单上。</p>
</div><p>While ProKidney currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 ProKidney 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

ProKidney (NASDAQ:PROK) 的股价下跌了 5.5% - 接下来会发生什么？